Bicycle Therapeutics is a biopharma company targeting unmet medical needs. Discover why BCYC stock benefits from strong ...

is composed of a CD79b-specific monoclonal antibody conjugated to a microtubule-disrupting agent called monomethyl auristatin E by a stable linker. CD79b is a transmembrane protein expressed on ...

This promising treatment, currently in Phase I trials, delivers a powerful cytotoxic punch using monomethyl auristatin E ...

【导读】胰腺癌是恶性最严重、死亡率最高的肿瘤之一，目前缺乏有效的药物。适配子-药物偶联物（ApDC）作为核酸药物的一种形式，在癌症治疗中 ...

Tivdak is a first-in-class therapy that combines an antibody target at tissue factor – a protein expressed on cervical cancer cells – with a cell-killing drug called monomethyl auristatin E.

NextCure (NXTC) reported pre-clinical data from LNCB74, a B7-H4-targeting antibody-drug conjugate, or ADC, being developed in partnership with ...

It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a ...

In an e-poster presented by Bicycle Therapeutics ... may be a primary driver of peripheral neuropathy rather than monomethyl auristatin E (MMAE) toxicity as was previously believed.

GSK’s team developed a second-generation route for manufacturing the cancer drug maleimidocaproyl monomethyl auristatin F (mcMMAF) which reduces solvent consumption by 16,160 kg per kilogram of ...

Promising initial Phase 1 data of EO-3021 reported in August highlighting 42.8% confirmed ORR observed in Claudin 18.2-enrich ...